EHA 2023 | Moving towards fixed-duration treatment in multiple myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, comments on the evidence supporting the shift towards a fixed-duration treatment paradigm for patients with multiple myeloma, highlighting trial data and the efficacy of newer strategies including quadruplet induction therapy and transplantation, CAR-T therapy, and bispecific antibodies. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanofi: Consultancy, Honoraria; Adaptive Biotechnologies: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Genentech: Research Funding; AbbVie: Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding.
